Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Manufacturing & Tech Ops | March 31, 2021 | April 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date March 31, 2021 · Filed April 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,776 |
Reported balance
After 2021-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-31 · Tax withholding · Disposed 159 · Balance 17,776 F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2021 Filed Apr 1, 2021 22:54 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 159 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000055 · wf-form4_161731759604526.xml · nonDerivative · entry 1 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 F1 · security: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 285 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · nonDerivative · entry 5 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,935 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 336 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · nonDerivative · entry 4 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,220 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 12,835 | $93.49 Strike: $93.49 | $1,199,944.15 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · derivative · entry 6 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,835 Underlying: Common Stock · 12,835 shares Expires 2028-02-23 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · nonDerivative · entry 3 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,556 F3 · security: Represents shares of common stock withheld to pay taxes. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · nonDerivative · entry 2 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,989 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000045 · wf-form4_161437776370492.xml · nonDerivative · entry 1 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,780 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleEmployee Stock Options (Right to Buy) · Derivative | 7,293 | $60.00 Strike: $30.63 | $437,580.00 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · derivative · entry 7 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,512 Underlying: Employee Stock Options (Right to Buy) · 7,293 shares Expires 2022-02-27 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleEmployee Stock Options (Right to Buy) · Derivative | 3,135 | $60.00 Strike: $30.86 | $188,100.00 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · derivative · entry 6 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,805 Underlying: Employee Stock Options (Right to Buy) · 3,135 shares Expires 2021-02-28 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,293 | $60.00 | $437,580.00 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · nonDerivative · entry 5 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,293 | $30.63 | $223,384.59 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · nonDerivative · entry 4 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,135 | $60.00 | $188,100.00 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · nonDerivative · entry 3 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,135 | $30.86 | $96,746.10 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · nonDerivative · entry 2 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. Read SEC document |
| April 06, 2020 Filed Apr 9, 2020 00:19 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,666 | $60.00 | $339,960.00 |
DisclosureSEC source: 0001367644-20-000033 · wf-form4_158639155760496.xml · nonDerivative · entry 1 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,571 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirk. F2 · kind: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 608 | $58.42 | $35,519.36 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · nonDerivative · entry 5 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,661 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 277 | $59.91 | $16,595.07 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · nonDerivative · entry 4 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,269 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 382 | $59.91 | $22,885.62 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · nonDerivative · entry 3 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,546 F3 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 14,648 | $61.44 Strike: $61.44 | $899,973.12 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · derivative · entry 6 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,668 Underlying: Common Stock · 14,648 shares Expires 2027-02-24 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · nonDerivative · entry 2 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,928 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:21 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 3,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000018 · wf-form4_158285647946534.xml · nonDerivative · entry 1 Kirk Sean · CIK 0001778426 · EVP, Manufacturing & Tech Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,266 F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.